Search Results
JEL Code: L65

137,026 Total downloads

Viewing: 51 - 100 of 671 papers

51.

Unsettling Drug Patent Settlements: A Framework for Presumptive Illegality

Michigan Law Review, Vol. 108
Number of pages: 44 Posted: 11 Mar 2009 Last Revised: 05 May 2015
Accepted Paper Series
Rutgers Law School
Downloads 536
52.

Forecasting Market Share in the US Pharmaceutical Market

Nature Reviews Drug Discovery. 2015. Vol. 14, No. 9: 594-595
Number of pages: 19 Posted: 18 Apr 2016
Accepted Paper Series
Novartis International AG and Duke University - Fuqua School of Business
Downloads 534
53.

Product Hopping: A New Framework

92 Notre Dame Law Review, 167 (2016)
Number of pages: 65 Posted: 16 Mar 2016 Last Revised: 25 Feb 2017
Accepted Paper Series
Rutgers Law School and Hilliard & Shadowen LLP
Downloads 533
54.

The Impact of Intellectual Capital on International Business – An Analysis of Investments in Intellectual Capital & Export Performance

Number of pages: 16 Posted: 08 Jun 2010
Working Paper Series
Pondicherry University, Karaikal Campus - School of Management and Indira Gandhi College of Arts and Science
Downloads 532
55.

Accounting Profitability and the Political Process: The Case of R&D Accounting in the Pharmaceutical Industry

Number of pages: 52 Posted: 29 Nov 2014 Last Revised: 28 Jan 2020
Working Paper Series
Lancaster University - Department of Accounting and Finance, Heinrich Heine University Dusseldorf - Duesseldorf Institute for Competition Economics (DICE) and WHU - Otto Beisheim School of Management
Downloads 527
56.

Valuation of Intangible Assets: Estimating Late-Stage Development Cost of Pharmaceutical R&D

Number of pages: 52 Posted: 12 Sep 2007
Working Paper Series
Institute of Leadership and Management in Health - Kingston University and Henley Management College - Henley Centre for Value Improvement (HCVI)
Downloads 520
57.

Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry

Number of pages: 59 Posted: 21 Oct 2003
Working Paper Series
Massachusetts Institute of Technology (MIT) - Department of Economics and Massachusetts Institute of Technology (MIT) - Department of Economics

Multiple version iconThere are 2 versions of this paper

Downloads 514
58.

Cartel Fine Severity and the European Commission: 2007-2011

European Competition Law Review 34 (2013): 58-77
Number of pages: 43 Posted: 13 Apr 2013
Accepted Paper Series
Purdue University
Downloads 513
59.

A Dynamic Oligopoly Structural Model for the Prescription Drug Market after Patent Expiration

International Economic Review, Vol. 51, No. 4, pp. 1175-1207, November 2010
Number of pages: 57 Posted: 16 Jun 2008 Last Revised: 31 Jul 2012
Accepted Paper Series
Johns Hopkins University - Carey Business School

Multiple version iconThere are 2 versions of this paper

Downloads 510
60.

Biologics: The New Antitrust Frontier

2018 U. Ill. L. Rev. 1 (2018)
Number of pages: 70 Posted: 08 Jun 2017 Last Revised: 31 Jan 2018
Accepted Paper Series
Rutgers Law School and Independent
Downloads 508
61.

A Critique of Partial Leniency for Cartels by the U.S. Department of Justice

Number of pages: 58 Posted: 06 Apr 2007 Last Revised: 09 Jun 2008
Working Paper Series
Purdue University
Downloads 498
62.

Citizen Petitions: Long, Late-Filed, and At-Last Denied

66 American University Law Review 305 (2016)
Number of pages: 48 Posted: 30 Aug 2016 Last Revised: 02 Jan 2017
Accepted Paper Series
Rutgers Law School and Independent
Downloads 498
63.

Ownership Vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D

McCombs Research Paper Series No. FIN-01-06, AFA 2006 Boston Meetings Paper
Number of pages: 56 Posted: 07 Mar 2005 Last Revised: 08 Feb 2014
Working Paper Series
Bates White, LLC

Multiple version iconThere are 2 versions of this paper

Downloads 494
64.

Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy

UPF Working Paper No. 662
Number of pages: 23 Posted: 03 Jun 2003
Working Paper Series
Universitat Pompeu Fabra - Faculty of Economic and Business Sciences
Downloads 494
65.

Common Ownership and Market Entry: Evidence from Pharmaceutical Industry

DIW Berlin Discussion Paper No. 1738
Number of pages: 59 Posted: 26 Jun 2018 Last Revised: 17 Nov 2019
Working Paper Series
KU Leuven, KU Leuven - Faculty of Business and Economics (FEB) and Universitat Pompeu Fabra - Department of Economics and Business (DEB)
Downloads 491
66.

'Branded Generics' as a Strategy to Limit Cannibalization of Pharmaceutical Markets

Managerial and Decision Economics, Jun-Aug 2007, Volume: 28, Issue: 4, pp. 251-265.
Number of pages: 38 Posted: 19 May 2005 Last Revised: 21 May 2012
Working Paper Series
U.S. Commodity Futures Trading Commission (CFTC) and University of Texas at Arlington - College of Business Administration - Department of Economics
Downloads 488
67.

Entry and Competition in Generic Biologics

Managerial and Decision Economics, 2007
Number of pages: 39 Posted: 17 Jul 2007 Last Revised: 20 Sep 2014
Accepted Paper Series
Duke University - Department of Economics, Duke University - Fuqua School of Business and Duke University - Medical Center
Downloads 485
68.

The Curious Incident of the Supreme Court in Myriad Genetics

Notre Dame Law Review, Vol. 90, No.2, 2014, pp.505-542, UC Irvine School of Law Research Paper No. 2014-29
Number of pages: 40 Posted: 12 Mar 2014 Last Revised: 06 Oct 2015
Accepted Paper Series
University of California, Irvine School of Law
Downloads 482
69.

Gene Concepts, Gene Talk, and Gene Patents

Minnesota Journal of Law, Science & Technology, Vol. 11, No. 1, pp. 157-191, 2010
Number of pages: 35 Posted: 14 May 2010
Accepted Paper Series
University of Kansas - School of Law
Downloads 477
70.

Intellectual Property Rights and Competition Policy with a Focus on Biotechnology

OECD, Best Practice Roundtables in Competition Policy Working Paper No. 50
Number of pages: 263 Posted: 04 Apr 2005 Last Revised: 22 Mar 2013
Working Paper Series
Organisation for Economic Co-Operation and Development (OECD), Directorate for Science, Technology and Innovation
Downloads 476
71.

A Dose of Competition: EU Antitrust Law in the Pharmaceuticals Sector

TILEC Discussion Paper No. 2015-017
Number of pages: 27 Posted: 04 Sep 2015 Last Revised: 11 Oct 2015
Working Paper Series
Tilburg Law School and Tilburg Law and Economics Center (TILEC)
Downloads 474
72.

Corporate Restructuring and R&D: A Panel Data Analysis for the Chemical Industry

IGIER Working Paper No. 173
Number of pages: 32 Posted: 01 Mar 2001
Working Paper Series
Duke University - Fuqua School of Business, Scheller College of Business at Georgia Tech and Tilburg University, Department of Finance
Downloads 474
73.

Internal Deadlines, Drug Approvals, and Safety Problems

Number of pages: 43 Posted: 30 Jul 2019 Last Revised: 15 Sep 2020
Working Paper Series
Harvard University - Business School (HBS), University of Texas at Dallas and Massachusetts Institute of Technology (MIT) - Sloan School of Management

Multiple version iconThere are 2 versions of this paper

Downloads 462
74.

The Trans-Pacific Partnership Agreement: Challenges for Australian Health and Medicine Policies

Medical Journal of Australia, Vol. 2, No. 194, pp. 83-86, 2011
Number of pages: 4 Posted: 17 Jan 2011
Accepted Paper Series
Australian National University and ANU College of Law
Downloads 460
75.

Activating Actavis with a More Complete Model

Antitrust, Forthcoming
Number of pages: 22 Posted: 31 Jan 2014
Accepted Paper Series
Economists Incorporated, Compass Lexecon, Economists Incorporated, University of Chicago, New York University (NYU) - Department of Economics, Princeton University - Princeton School of Public and International Affairs and Economists Incorporated
Downloads 458
76.

Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration

International Journal of Industrial Organization, Vol. 28, No. 6, pp. 619-638, November 2010
Number of pages: 67 Posted: 19 Feb 2008 Last Revised: 30 Jul 2012
Accepted Paper Series
Johns Hopkins University - Carey Business School
Downloads 457
77.

The Problem of Process in Biotechnology

Houston Law Review, Vol. 43, p. 561, 2006, Minnesota Legal Studies Research Paper No. 06-57
Number of pages: 31 Posted: 17 Oct 2006
Accepted Paper Series
University of California, Irvine School of Law
Downloads 456
78.

Manufacturing Barriers to Biologics Competition and Innovation

101 Iowa L. Rev. 1023 (2016), Duke Law School Public Law & Legal Theory Series No. 2015-20, Duke I&E Research Paper No. 15-2
Number of pages: 41 Posted: 16 Apr 2015 Last Revised: 30 Jul 2018
Accepted Paper Series
University of Michigan Law School and Duke University School of Law
Downloads 450
79.

Competition and R&D Financing: Evidence from the Biopharmaceutical Industry

MIT Sloan Research Paper No. 5140-15
Number of pages: 49 Posted: 25 Jan 2015 Last Revised: 12 Feb 2018
Working Paper Series
University of Minnesota - Carlson School of Management and Massachusetts Institute of Technology (MIT) - Laboratory for Financial Engineering

Multiple version iconThere are 2 versions of this paper

Downloads 447
80.

Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing

55 B.C. L. Rev. 491 (2014)
Number of pages: 72 Posted: 18 Aug 2013 Last Revised: 03 Apr 2016
Accepted Paper Series
University of Michigan Law School
Downloads 446
81.

Payment after Actavis

100 Iowa Law Review 7 (2014)
Number of pages: 43 Posted: 02 Apr 2014 Last Revised: 30 Dec 2014
Accepted Paper Series
Rutgers Law School
Downloads 446
82.

The Effects of Publicity on Demand: The Case of Anti-Cholesterol Drugs

Published in Marketing Science 35(1):158-181, 2016, Rotman School of Management Working Paper No. 1782055
Number of pages: 54 Posted: 09 Mar 2011 Last Revised: 08 May 2020
Working Paper Series
Johns Hopkins University - Carey Business School, HEC Montreal, University of Toronto - Rotman School of Management and York University
Downloads 446
83.

Counterfeit Drugs: The Consumer Perspective

Number of pages: 17 Posted: 28 Nov 2007
Working Paper Series
University of Connecticut - School of Business
Downloads 437
84.

DNA Copyright

Valparaiso University Law Review, Vol. 46, pp. 1-41, 2011
Number of pages: 41 Posted: 11 Mar 2012
Accepted Paper Series
University of Kansas - School of Law
Downloads 436
85.

US Pharma's Financialized Business Model

Institute for New Economic Thinking Working Paper Series No. 60
Number of pages: 27 Posted: 13 Sep 2017
Working Paper Series
The Academic-Industry Research Network, The Academic-Industry Research Network, The Academic-Industry Research Network, The Academic-Industry Research Network and SOAS University of London
Downloads 429
86.

Citizen Petitions: An Empirical Study

Cardozo Law Review, Forthcoming
Number of pages: 46 Posted: 04 Jun 2012 Last Revised: 30 Jul 2013
Accepted Paper Series
Rutgers Law School and affiliation not provided to SSRN
Downloads 417
87.

Global Cartels Redux: The Amino Acid Lysine Antitrust Litigation 1996

Number of pages: 37 Posted: 28 May 2009
Working Paper Series
Purdue University

Multiple version iconThere are 2 versions of this paper

Downloads 416
88.

The Concept of an Agreement and Beyond: How to Block Parallel Imports of Pharmaceuticals to Protect the Heart of Competition

EC COMPETITION LAW A CRITICAL ASSESSMENT, Giuliano Amato, Claus-Dieter Ehlermann, eds., pp. 81-142, Hart Publishing, 2007
Number of pages: 62 Posted: 06 Dec 2007
Accepted Paper Series
European University Institute
Downloads 415
89.

Patent and Antitrust: Differing Shades of Meaning

Virginia Journal of Law and Technology, Vol. 13, No. 2, 2008
Number of pages: 19 Posted: 02 May 2008
Accepted Paper Series
UC Hastings Law
Downloads 412
90.

Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry

Number of pages: 47 Posted: 29 Apr 2012 Last Revised: 19 Apr 2016
Working Paper Series
University of Virginia - Department of Economics, University of Virginia - Department of Economics, Cornell University and University of Cergy-Pontoise

Multiple version iconThere are 3 versions of this paper

Downloads 409
91.

Evolution of the Global Lysine Industry, 1960-2000

Chapter 8, pp. 237-66 in Innovation in the Food & Drink Industry, Ruth Rama (ed.). New York: Haworth Press (April 2008)
Number of pages: 28 Posted: 30 Jul 2008 Last Revised: 09 Mar 2013
Accepted Paper Series
Purdue University
Downloads 407
92.

Excessive Drug Pricing as an Antitrust Violation

82 Antitrust Law Journal 701 (2019), NYU Law and Economics Research Paper No. 19-16
Number of pages: 41 Posted: 20 Jan 2019 Last Revised: 04 Jul 2019
Accepted Paper Series
New York University School of Law
Downloads 406
93.

The Cost Effectiveness of Direct to Consumer Advertising for Prescription Drugs

Emory Law and Economics Research Paper No. 08-28
Number of pages: 30 Posted: 12 Feb 2008
Working Paper Series
1350 Main St UNIT 1703 and Emory University - Department of Health Policy and Management
Downloads 391
94.

Basic Chemical Industry of India: An Analysis

Number of pages: 16 Posted: 29 Apr 2008
Working Paper Series
Indira Gandhi Institute of Development Research (IGIDR)
Downloads 390
95.

Searching for the Profit in Pollution Prevention: Case Studies in the Corporate Evaluation of Environmental Opportunities

Discussion Paper 98-30
Number of pages: 48 Posted: 07 May 1998
Working Paper Series
Resources for the Future
Downloads 390
96.

Sharing R&D Risk in Healthcare via FDA Hedges

MIT Sloan Research Paper No. 5194-17
Number of pages: 51 Posted: 03 Apr 2017 Last Revised: 13 Apr 2017
Working Paper Series
Boston College - Carroll School of Management, Massachusetts Institute of Technology (MIT) - Laboratory for Financial Engineering, University of Chicago, Goldman Sachs and University of Minnesota - Carlson School of Management

Multiple version iconThere are 2 versions of this paper

Downloads 385
97.
Downloads 381
98.

Financial Analysts Impact on Stock Volatility: A Study on the Pharmaceutical Sector

FEDEA Working Paper No. 2008-19
Number of pages: 30 Posted: 14 May 2008
Working Paper Series
Banco de España and Banco de España

Multiple version iconThere are 2 versions of this paper

Downloads 378
99.

Playing Both Sides: Branded Sales, Generic Drugs, and Antitrust Policy

Stanford Law and Economics Olin Working Paper No. 533, 71 Hastings Law Journal 307 (2020), Rutgers Law School Research Paper
Number of pages: 52 Posted: 12 Mar 2019 Last Revised: 21 Feb 2020
Accepted Paper Series
Rutgers Law School, Stanford Law School and University of San Diego School of Law
Downloads 376
100.

The Value of Intellectual Assets in Indian Pharmaceutical Industry: An Empirical Study of the Components of Market Value

Number of pages: 28 Posted: 12 Mar 2009
Working Paper Series
Pondicherry University, Karaikal Campus - School of Management and Indira Gandhi College of Arts and Science
Downloads 373